{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:11:55Z","timestamp":1781629915678,"version":"3.54.5"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Key R&D Program of Zhejiang Province","award":["2020C03010"],"award-info":[{"award-number":["2020C03010"]}]},{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"crossref","award":["21575128"],"award-info":[{"award-number":["21575128"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"crossref","award":["81773632"],"award-info":[{"award-number":["81773632"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LZ19H300001"],"award-info":[{"award-number":["LZ19H300001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cheminform"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Breast cancer resistance protein (BCRP\/ABCG2), an ATP-binding cassette (ABC) efflux transporter, plays a critical role in multi-drug resistance (MDR) to anti-cancer drugs and drug\u2013drug interactions. The prediction of BCRP inhibition can facilitate evaluating potential drug resistance and drug\u2013drug interactions in early stage of drug discovery. Here we reported a structurally diverse dataset consisting of 1098 BCRP inhibitors and 1701 non-inhibitors. Analysis of various physicochemical properties illustrates that BCRP inhibitors are more hydrophobic and aromatic than non-inhibitors. We then developed a series of quantitative structure\u2013activity relationship (QSAR) models to discriminate between\u00a0BCRP inhibitors and non-inhibitors. The optimal feature subset was determined by a wrapper feature selection method named rfSA (simulated annealing algorithm coupled with random forest), and the classification models were established by using seven machine learning approaches based on the optimal feature subset, including a deep learning method, two ensemble learning methods, and four classical machine learning methods. The statistical results demonstrated that three methods, including support vector machine (SVM), deep neural networks (DNN) and extreme gradient boosting (XGBoost), outperformed the others, and the SVM classifier yielded the best predictions (MCC\u2009=\u20090.812 and AUC\u2009=\u20090.958 for the test set). Then, a perturbation-based model-agnostic method was used to interpret our models and analyze the representative features for different models. The application domain analysis demonstrated the prediction reliability of our models. Moreover, the important structural fragments related to BCRP inhibition were identified by the information gain (IG) method along with the frequency analysis. In conclusion, we believe that the classification models developed in this study can be regarded as simple and accurate tools to distinguish BCRP inhibitors from non-inhibitors in drug design and discovery pipelines.<\/jats:p>","DOI":"10.1186\/s13321-020-00421-y","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T13:02:52Z","timestamp":1583413372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["ADMET evaluation in drug discovery. 20. Prediction of breast cancer resistance protein inhibition through machine learning"],"prefix":"10.1186","volume":"12","author":[{"given":"Dejun","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tailong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7227-2580","authenticated-orcid":false,"given":"Tingjun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"421_CR1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2174\/138920010792927325","volume":"11","author":"Z Ni","year":"2010","unstructured":"Ni Z, Bikadi Z, Rosenberg MF, Mao Q (2010) Structure and function of the human breast cancer resistance protein (BCRP\/ABCG2). Curr Drug Metab 11:603\u2013617","journal-title":"Curr Drug Metab"},{"key":"421_CR2","doi-asserted-by":"publisher","first-page":"E118","DOI":"10.1208\/aapsj070112","volume":"7","author":"QC Mao","year":"2005","unstructured":"Mao QC, Unadkat JD (2005) Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 7:E118\u2013E133","journal-title":"AAPS J"},{"key":"421_CR3","doi-asserted-by":"publisher","first-page":"7340","DOI":"10.1038\/sj.onc.1206938","volume":"22","author":"LA Doyle","year":"2003","unstructured":"Doyle LA, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340\u20137358","journal-title":"Oncogene"},{"key":"421_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","volume":"17","author":"Q Mao","year":"2015","unstructured":"Mao Q, Unadkat JD (2015) Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport-an update. AAPS J 17:65\u201382","journal-title":"AAPS J"},{"key":"421_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11030-014-9562-2","volume":"19","author":"P Garg","year":"2015","unstructured":"Garg P, Dhakne R, Belekar V (2015) Role of breast cancer resistance protein (BCRP) as active efflux transporter on blood\u2013brain barrier (BBB) permeability. Mol Divers 19:163\u2013172","journal-title":"Mol Divers"},{"key":"421_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.drudis.2007.12.010","volume":"13","author":"G Szakacs","year":"2008","unstructured":"Szakacs G, Varadi A, Oezvegy-Laczka C, Sarkadi B (2008) The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 13:379\u2013393","journal-title":"Drug Discov Today"},{"key":"421_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1146\/annurev.pharmtox.46.120604.141238","volume":"46","author":"P Krishnamurthy","year":"2006","unstructured":"Krishnamurthy P, Schuetz J (2006) Role of ABCG2\/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol 46:381\u2013410","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"421_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejps.2009.05.012","volume":"38","author":"E Nicolle","year":"2009","unstructured":"Nicolle E, Boccard J, Guilet D, Dijoux-Franca M-G, Zelefac F, Macalou S, Grosselin J, Schmidt J, Carrupt P-A, Di Pietro A, Boumendjel A (2009) Breast cancer resistance protein (BCRP\/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach. Eur J Pharm Sci 38:39\u201346","journal-title":"Eur J Pharm Sci"},{"key":"421_CR9","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1200\/JCO.2002.12.116","volume":"20","author":"CMF Kruijtzer","year":"2002","unstructured":"Kruijtzer CMF, Beijnen JH, Rosing H, Huinink WWT, Schot M, Jewell RC, Paul EM, Schellens JHM (2002) Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20:2943\u20132950","journal-title":"J Clin Oncol"},{"key":"421_CR10","doi-asserted-by":"publisher","first-page":"7491","DOI":"10.1158\/0008-5472.CAN-04-0096","volume":"64","author":"CF Stewart","year":"2004","unstructured":"Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins JJ, Gilbertson R, Germain GS, Harwood FC, Houghton PJ (2004) Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64:7491\u20137499","journal-title":"Cancer Res"},{"key":"421_CR11","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1021\/mp300547h","volume":"10","author":"Y Pan","year":"2013","unstructured":"Pan Y, Chothe PP, Swaan PW (2013) Identification of novel breast cancer resistance protein (BCRP) inhibitors by virtual screening. Mol Pharm 10:1236\u20131248","journal-title":"Mol Pharm"},{"key":"421_CR12","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1016\/j.bmc.2010.12.043","volume":"19","author":"A Pick","year":"2011","unstructured":"Pick A, Mueller H, Mayer R, Haenisch B, Pajeva IK, Weigt M, Boenisch H, Mueller CE, Wiese M (2011) Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorg Med Chem 19:2090\u20132102","journal-title":"Bioorg Med Chem"},{"key":"421_CR13","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1124\/jpet.105.099036","volume":"317","author":"H Saito","year":"2006","unstructured":"Saito H, Hirano H, Nakagawa H, Fukami T, Oosumi K, Murakami K, Kimura H, Kouchi T, Konomi M, Tao E, Tsujikawa N, Tarui S, Nagakura M, Osumi M, Ishikawa T (2006) A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. J Pharmacol Exp Ther 317:1114\u20131124","journal-title":"J Pharmacol Exp Ther"},{"key":"421_CR14","doi-asserted-by":"publisher","first-page":"8224","DOI":"10.1016\/j.bmc.2008.07.034","volume":"16","author":"A Pick","year":"2008","unstructured":"Pick A, Mueller H, Wiese M (2008) Structure\u2013activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). Bioorg Med Chem 16:8224\u20138236","journal-title":"Bioorg Med Chem"},{"key":"421_CR15","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.bcp.2005.05.017","volume":"70","author":"SZ Zhang","year":"2005","unstructured":"Zhang SZ, Yang XN, Coburn RA, Morris ME (2005) Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol 70:627\u2013639","journal-title":"Biochem Pharmacol"},{"key":"421_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1124\/jpet.107.124768","volume":"323","author":"P Matsson","year":"2007","unstructured":"Matsson P, Englund G, Ahlin G, Bergstrom CAS, Norinder U, Artursson P (2007) A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2). J Pharmacol Exp Ther 323:19\u201330","journal-title":"J Pharmacol Exp Ther"},{"key":"421_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1208\/s12248-009-9132-1","volume":"11","author":"YA Gandhi","year":"2009","unstructured":"Gandhi YA, Morris ME (2009) Structure\u2013activity relationships and quantitative structure\u2013activity relationships for breast cancer resistance protein (ABCG2). AAPS J 11:541\u2013552","journal-title":"AAPS J"},{"key":"421_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2174\/138955712800493825","volume":"12","author":"T Ishikawa","year":"2012","unstructured":"Ishikawa T, Hirano H, Saito H, Sano K, Ikegami Y, Yamaotsu N, Hirono S (2012) Quantitative structure\u2013activity relationship (QSAR) Analysis to predict drug\u2013drug interactions of ABC transporter ABCG2. Mini-Rev Med Chem 12:505\u2013514","journal-title":"Mini-Rev Med Chem"},{"key":"421_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.addr.2008.10.004","volume":"61","author":"E Nicolle","year":"2009","unstructured":"Nicolle E, Boumendjel A, Macalou S, Genoux E, Ahmed-Belkacem A, Carrupt PA, Di Pietro A (2009) QSAR analysis and molecular modeling of ABCG2-specific inhibitors. Adv Drug Deliv Rev 61:34\u201346","journal-title":"Adv Drug Deliv Rev"},{"key":"421_CR20","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/minf.201400012","volume":"33","author":"F Montanari","year":"2014","unstructured":"Montanari F, Ecker GF (2014) BCRP inhibition: from data collection to ligand-based modeling. Mol Inform 33:322\u2013331","journal-title":"Mol Inform"},{"key":"421_CR21","doi-asserted-by":"publisher","first-page":"476","DOI":"10.2174\/1386207318666150525094503","volume":"18","author":"V Belekar","year":"2015","unstructured":"Belekar V, Lingineni K, Garg P (2015) Classification of breast cancer resistant protein (BCRP) inhibitors and non-inhibitors using machine learning approaches. Comb Chem High Throughput Screen 18:476\u2013485","journal-title":"Comb Chem High Throughput Screen"},{"key":"421_CR22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/1087057116657513","volume":"22","author":"F Montanari","year":"2017","unstructured":"Montanari F, Cseke A, Wlcek K, Ecker GF (2017) Virtual screening of DrugBank Reveals two drugs as new BCRP inhibitors. Slas Discov 22:86\u201393","journal-title":"Slas Discov"},{"key":"421_CR23","doi-asserted-by":"publisher","first-page":"E4304","DOI":"10.1073\/pnas.1803294115","volume":"115","author":"JY Ryu","year":"2018","unstructured":"Ryu JY, Kim HU, Lee SY (2018) Deep learning improves prediction of drug\u2013drug and drug\u2013food interactions. Proc Natl Acad Sci 115:E4304\u2013E4311","journal-title":"Proc Natl Acad Sci"},{"key":"421_CR24","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3390\/cancers11091235","volume":"11","author":"K Munir","year":"2019","unstructured":"Munir K, Elahi H, Ayub A, Frezza F, Rizzi A (2019) Cancer diagnosis using deep learning: a bibliographic review. Cancers 11:1235","journal-title":"Cancers"},{"key":"421_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1021\/ci500747n","volume":"55","author":"J Ma","year":"2015","unstructured":"Ma J, Sheridan RP, Liaw A, Dahl GE, Svetnik V (2015) Deep neural nets as a method for quantitative structure\u2013activity relationships. J Chem Inf Model 55:263\u2013274","journal-title":"J Chem Inf Model"},{"key":"421_CR26","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.toxlet.2017.07.175","volume":"280","author":"G Klambauer","year":"2017","unstructured":"Klambauer G, Unterthiner T, Mayr A, Hochreiter S (2017) DeepTox: toxicity prediction using deep learning. Toxicol Lett 280:S69\u2013S69","journal-title":"Toxicol Lett"},{"key":"421_CR27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1039\/C7SC02664A","volume":"9","author":"Z Wu","year":"2018","unstructured":"Wu Z, Ramsundar B, Feinberg EN, Gomes J, Geniesse C, Pappu AS, Leswing K, Pande V (2018) MoleculeNet: a benchmark for molecular machine learning. Chem Sci 9:513\u2013530","journal-title":"Chem Sci"},{"key":"421_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1021\/acscentsci.6b00367","volume":"3","author":"H Altae-Tran","year":"2017","unstructured":"Altae-Tran H, Ramsundar B, Pappu AS, Pande V (2017) Low data drug discovery with one-shot learning. ACS Cent Sci 3:283\u2013293","journal-title":"ACS Cent Sci"},{"key":"421_CR29","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1021\/acs.molpharmaceut.7b00317","volume":"14","author":"T Lei","year":"2017","unstructured":"Lei T, Chen F, Liu H, Sun H, Kang Y, Li D, Li Y, Hou T (2017) ADMET evaluation in drug discovery. Part 17: development of quantitative and qualitative prediction models for chemical-induced respiratory toxicity. Mol Pharm 14:2407\u20132421","journal-title":"Mol Pharm"},{"key":"421_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13321-016-0117-7","volume":"8","author":"T Lei","year":"2016","unstructured":"Lei T, Li Y, Song Y, Li D, Sun H, Hou T (2016) ADMET evaluation in drug discovery: 15. Accurate prediction of rat oral acute toxicity using relevance vector machine and consensus modeling. J Cheminform 8:6","journal-title":"J Cheminform"},{"key":"421_CR31","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1021\/acs.jcim.6b00591","volume":"56","author":"RP Sheridan","year":"2016","unstructured":"Sheridan RP, Wang WM, Liaw A, Ma J, Gifford EM (2016) Extreme gradient boosting as a method for quantitative structure\u2013activity relationships. J Chem Inf Model 56:2353\u20132360","journal-title":"J Chem Inf Model"},{"key":"421_CR32","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1021\/acs.molpharmaceut.7b00578","volume":"14","author":"A Korotcov","year":"2017","unstructured":"Korotcov A, Tkachenko V, Russo DP, Ekins S (2017) Comparison of deep learning with multiple machine learning methods and metrics using diverse drug discovery data sets. Mol Pharm 14:4462\u20134475","journal-title":"Mol Pharm"},{"key":"421_CR33","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1021\/acs.molpharmaceut.6b00248","volume":"13","author":"A Aliper","year":"2016","unstructured":"Aliper A, Plis S, Artemov A, Ulloa A, Mamoshina P, Zhavoronkov A (2016) Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data. Mol Pharm 13:2524\u20132530","journal-title":"Mol Pharm"},{"key":"421_CR34","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/17460441.2018.1465407","volume":"13","author":"E Gawehn","year":"2018","unstructured":"Gawehn E, Hiss JA, Brown JB, Schneider G (2018) Advancing drug discovery via GPU-based deep learning. Expert Opin Drug Discov 13:579\u2013582","journal-title":"Expert Opin Drug Discov"},{"key":"421_CR35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/bdd.2022","volume":"37","author":"R D\u2019Cunha","year":"2016","unstructured":"D\u2019Cunha R, Bae S, Murry DJ, An G (2016) TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux. Biopharm Drug Dispos 37:397\u2013408","journal-title":"Biopharm Drug Dispos"},{"key":"421_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejps.2011.03.006","volume":"43","author":"R Elsby","year":"2011","unstructured":"Elsby R, Fox L, Stresser D, Layton M, Butters C, Sharma P, Smith V, Surry D (2011) In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug\u2013drug interaction with methotrexate. Eur J Pharm Sci 43:41\u201349","journal-title":"Eur J Pharm Sci"},{"key":"421_CR37","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/jps.24289","volume":"104","author":"B Fleisher","year":"2015","unstructured":"Fleisher B, Unum J, Shao J, An G (2015) Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage\u2013drug interaction. J Pharm Sci 104:266\u2013275","journal-title":"J Pharm Sci"},{"key":"421_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1021\/jm500943z","volume":"58","author":"GJ Gozzi","year":"2015","unstructured":"Gozzi GJ, Bouaziz Z, Winter E, Daflon-Yunes N, Aichele D, Nacereddine A, Marminon C, Valdameri G, Zeinyeh W, Bollacke A, Guillon J, Lacoudre A, Pinaud N, Cadena SM, Jose J, Le Borgne M, Di Pietro A (2015) Converting potent indeno 1,2-b indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2. J Med Chem 58:265\u2013277","journal-title":"J Med Chem"},{"key":"421_CR39","first-page":"3481","volume":"9","author":"GJ Gozzi","year":"2015","unstructured":"Gozzi GJ, Bouaziz Z, Winter E, Daflon-Yunes N, Honorat M, Guragossian N, Marminon C, Valdameri G, Bollacke A, Guillon J, Pinaud N, Marchivie M, Cadena SM, Jose J, Le Borgne M, Di Pietro A (2015) Phenolic indeno 1,2-b indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity. Drug Des Dev Ther 9:3481\u20133495","journal-title":"Drug Des Dev Ther"},{"key":"421_CR40","doi-asserted-by":"publisher","first-page":"5407","DOI":"10.1016\/j.bmc.2013.06.018","volume":"21","author":"G Gros","year":"2013","unstructured":"Gros G, Martinez L, Gimenez AS, Adler P, Maurin P, Wolkowicz R, Falson P, Hasserodt J (2013) Modular construction of quaternary hemiaminal-based inhibitor candidates and their in cellulo assessment with HIV-1 protease. Bioorg Med Chem 21:5407\u20135413","journal-title":"Bioorg Med Chem"},{"key":"421_CR41","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.bbrc.2014.11.016","volume":"455","author":"X Gu","year":"2014","unstructured":"Gu X, Ren Z, Peng H, Peng S, Zhang Y (2014) Bifendate-chalcone hybrids: a new class of potential dual inhibitors of P-glycoprotein and breast cancer resistance protein. Biochem Biophys Res Commun 455:318\u2013322","journal-title":"Biochem Biophys Res Commun"},{"key":"421_CR42","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1016\/j.bmcl.2014.05.081","volume":"24","author":"X Gu","year":"2014","unstructured":"Gu X, Tang X, Zhao Q, Peng H, Peng S, Zhang Y (2014) Discovery of alkoxyl biphenyl derivatives bearing dibenzo c, e azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein. Bioorg Med Chem Lett 24:3419\u20133421","journal-title":"Bioorg Med Chem Lett"},{"key":"421_CR43","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.1016\/j.bmcl.2017.09.009","volume":"27","author":"NA Gujarati","year":"2017","unstructured":"Gujarati NA, Zeng L, Gupta P, Chen Z-S, Korlipara VL (2017) Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors. Bioorg Med Chem Lett 27:4698\u20134704","journal-title":"Bioorg Med Chem Lett"},{"key":"421_CR44","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejps.2008.06.001","volume":"35","author":"Y Han","year":"2008","unstructured":"Han Y, Riwanto M, Go M-L, Ee PLR (2008) Modulation of breast cancer resistance protein (BCRP\/ABCG2) by non-basic chalcone analogues. Eur J Pharm Sci 35:30\u201341","journal-title":"Eur J Pharm Sci"},{"key":"421_CR45","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.bmc.2015.03.017","volume":"23","author":"D Hayashi","year":"2015","unstructured":"Hayashi D, Tsukioka N, Inoue Y, Matsubayashi Y, Iizuka T, Higuchi K, Ikegami Y, Kawasaki T (2015) Synthesis and ABCG2 inhibitory evaluation of 5-N-acetylardeemin derivatives. Bioorg Med Chem 23:2010\u20132023","journal-title":"Bioorg Med Chem"},{"key":"421_CR46","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1177\/1087057105284576","volume":"11","author":"CJ Henrich","year":"2006","unstructured":"Henrich CJ, Bokesch HR, Dean M, Bates SE, Robey RW, Goncharova EI, Wilson JA, McMahon JB (2006) A high-throughput cell-based assay for inhibitors of ABCG2 activity. J Biomol Screen 11:176\u2013183","journal-title":"J Biomol Screen"},{"key":"421_CR47","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1021\/cb900134c","volume":"4","author":"CJ Henrich","year":"2009","unstructured":"Henrich CJ, Robey RW, Takada K, Bokesch HR, Bates SE, Shukla S, Ambudkar SV, McMahon JB, Gustafson KR (2009) Botryllamides: natural product inhibitors of ABCG2. ACS Chem Biol 4:637\u2013647","journal-title":"ACS Chem Biol"},{"key":"421_CR48","doi-asserted-by":"publisher","first-page":"7858","DOI":"10.1016\/j.bmc.2013.10.007","volume":"21","author":"K Juvale","year":"2013","unstructured":"Juvale K, Gallus J, Wiese M (2013) Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2). Bioorg Med Chem 21:7858\u20137873","journal-title":"Bioorg Med Chem"},{"key":"421_CR49","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejmech.2013.06.035","volume":"67","author":"K Juvale","year":"2013","unstructured":"Juvale K, Stefan K, Wiese M (2013) Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP\/ABCG2. Eur J Med Chem 67:115\u2013126","journal-title":"Eur J Med Chem"},{"key":"421_CR50","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.canlet.2016.03.030","volume":"376","author":"C Karthikeyan","year":"2016","unstructured":"Karthikeyan C, Malla R, Ashby CR Jr., Amawi H, Abbott KL, Moore J, Chen J, Balch C, Lee C, Flannery PC, Trivedi P, Faridi JS, Pondugula SR, Tiwari AK (2016) Pyrimido 1\u2033, 2\u2033:1,5 pyrazolo 3,4-b quinolines: novel compounds that reverse ABCG2-mediated resistance in cancer cells. Cancer Lett 376:118\u2013126","journal-title":"Cancer Lett"},{"key":"421_CR51","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/mnfr.201400288","volume":"58","author":"WT Kee","year":"2014","unstructured":"Kee WT, Cooney J, Jensen D, Yan L, Paxton JW, Birch NP, Scheepens A (2014) Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP\/ABCG2). Mol Nutr Food Res 58:2099\u20132110","journal-title":"Mol Nutr Food Res"},{"key":"421_CR52","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.ejmech.2016.09.010","volume":"124","author":"SC Koehler","year":"2016","unstructured":"Koehler SC, Silbermann K, Wiese M (2016) Phenyltetrazolyl-phenylamides: substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter. Eur J Med Chem 124:881\u2013895","journal-title":"Eur J Med Chem"},{"key":"421_CR53","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ejmech.2018.01.012","volume":"146","author":"SC Koehler","year":"2018","unstructured":"Koehler SC, Vandati S, Scholz MS, Wiese M (2018) Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors. Eur J Med Chem 146:483\u2013500","journal-title":"Eur J Med Chem"},{"key":"421_CR54","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1021\/acs.jmedchem.5b00188","volume":"58","author":"SC Koehler","year":"2015","unstructured":"Koehler SC, Wiese M (2015) HM30181 derivatives as novel potent and selective inhibitors of the breast cancer resistance protein (BCRP\/ABCG2). J Med Chem 58:3910\u20133921","journal-title":"J Med Chem"},{"key":"421_CR55","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1002\/cmdc.201600341","volume":"11","author":"S Kraege","year":"2016","unstructured":"Kraege S, Koehler SC, Wiese M (2016) Acryloylphenylcarboxamides: a new class of breast cancer resistance protein (ABCG2) modulators. ChemMedChem 11:2422\u20132435","journal-title":"ChemMedChem"},{"key":"421_CR56","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ejmech.2016.03.067","volume":"117","author":"S Kraege","year":"2016","unstructured":"Kraege S, Stefan K, Juvale K, Ross T, Willmes T, Wiese M (2016) The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP\/ABCG2). Eur J Med Chem 117:212\u2013229","journal-title":"Eur J Med Chem"},{"key":"421_CR57","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1002\/cmdc.201600455","volume":"11","author":"S Kraege","year":"2016","unstructured":"Kraege S, Stefan K, Koehler SC, Wiese M (2016) Optimization of Acryloylphenylcarboxamides as inhibitors of ABCG2 and comparison with acryloylphenylcarboxylates. ChemMedChem 11:2547\u20132558","journal-title":"ChemMedChem"},{"key":"421_CR58","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1021\/acs.jmedchem.7b01012","volume":"61","author":"MK Krapf","year":"2018","unstructured":"Krapf MK, Gallus J, Vahdati S, Wiese M (2018) New inhibitors of breast cancer resistance protein (ABCG2) containing a 2,4-disubstituted pyridopyrimidine scaffold. J Med Chem 61:3389\u20133408","journal-title":"J Med Chem"},{"key":"421_CR59","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ejmech.2017.08.020","volume":"139","author":"MK Krapf","year":"2017","unstructured":"Krapf MK, Gallus J, Wiese M (2017) Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2). Eur J Med Chem 139:587\u2013611","journal-title":"Eur J Med Chem"},{"key":"421_CR60","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.1021\/acs.jmedchem.7b00441","volume":"60","author":"MK Krapf","year":"2017","unstructured":"Krapf MK, Gallus J, Wiese M (2017) 4-Anilino-2-pyridylquinazolines and -pyrimidines as highly potent and nontoxic inhibitors of breast cancer resistance protein (ABCG2). J Med Chem 60:4474\u20134495","journal-title":"J Med Chem"},{"key":"421_CR61","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1021\/acs.jmedchem.6b00330","volume":"59","author":"MK Krapf","year":"2016","unstructured":"Krapf MK, Wiese M (2016) Synthesis and biological evaluation of 4-anilino-quinazolines and -quinolines as inhibitors of breast cancer resistance protein (ABCG2). J Med Chem 59:5449\u20135461","journal-title":"J Med Chem"},{"key":"421_CR62","doi-asserted-by":"publisher","first-page":"5860","DOI":"10.1016\/j.bmc.2014.09.023","volume":"22","author":"A Krauze","year":"2014","unstructured":"Krauze A, Grinberga S, Krasnova L, Adlere I, Sokolova E, Domracheva I, Shestakova I, Andzans Z, Duburs G (2014) Thieno 2,3-b pyridines-A new class of multidrug resistance (MDR) modulators. Bioorg Med Chem 22:5860\u20135870","journal-title":"Bioorg Med Chem"},{"key":"421_CR63","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ejmech.2015.06.049","volume":"101","author":"X-Q Li","year":"2015","unstructured":"Li X-Q, Wang L, Lei Y, Hu T, Zhang F-L, Cho C-H, To KKW (2015) Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives. Eur J Med Chem 101:560\u2013572","journal-title":"Eur J Med Chem"},{"key":"421_CR64","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.bmcl.2015.11.077","volume":"26","author":"Y Li","year":"2016","unstructured":"Li Y, Woo J, Chmielecki J, Xia CQ, Liao M, Chuang B-C, Yang JJ, Guan MY, Plesescu M, Prakash SR (2016) Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles. Bioorg Med Chem Lett 26:551\u2013555","journal-title":"Bioorg Med Chem Lett"},{"key":"421_CR65","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/cmdc.201402498","volume":"10","author":"F Marighetti","year":"2015","unstructured":"Marighetti F, Steggemann K, Karbaum M, Wiese M (2015) Scaffold identification of a new class of potent and selective BCRP inhibitors. ChemMedChem 10:742\u2013751","journal-title":"ChemMedChem"},{"key":"421_CR66","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3389\/fphar.2016.00518","volume":"7","author":"H Miyata","year":"2016","unstructured":"Miyata H, Takada T, Toyoda Y, Matsuo H, Ichida K, Suzuki H (2016) Identification of febuxostat as a new strong ABCG2 inhibitor: potential applications and risks in clinical situations. Front Pharmacol 7:518","journal-title":"Front Pharmacol"},{"key":"421_CR67","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1021\/ml4000832","volume":"4","author":"C Ochoa-Puentes","year":"2013","unstructured":"Ochoa-Puentes C, Bauer S, Kuehnle M, Bernhard G, Buschauer A, Koenig B (2013) Benzanilide-biphenyl replacement: a bioisosteric approach to quinoline carboxamide-type ABCG2 modulators. ACS Med Chem Lett 4:393\u2013396","journal-title":"ACS Med Chem Lett"},{"key":"421_CR68","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ejmech.2016.05.053","volume":"122","author":"ARA Pires","year":"2016","unstructured":"Pires ARA, Lecerf-Schmidt F, Guragossian N, Pazinato J, Gozzi GJ, Winter E, Valdameri G, Veale A, Boumendjel A, Di Pietro A, Peres B (2016) New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2. Eur J Med Chem 122:291\u2013301","journal-title":"Eur J Med Chem"},{"key":"421_CR69","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.bcp.2014.12.012","volume":"93","author":"JL Revalde","year":"2015","unstructured":"Revalde JL, Li Y, Hawkins BC, Rosengren RJ, Paxton JW (2015) Heterocyclic cyclohexanone monocarbonyl analogs of curcumin can inhibit the activity of ATP-binding cassette transporters in cancer multidrug resistance. Biochem Pharmacol 93:305\u2013317","journal-title":"Biochem Pharmacol"},{"key":"421_CR70","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/ijerph13010017","volume":"13","author":"C Schexnayder","year":"2016","unstructured":"Schexnayder C, Stratford RE (2016) Genistein and glyceollin effects on ABCC2 (MRP2) and ABCG2 (BCRP) in Caco-2 cells. Int J Environ Res Public Health 13:17","journal-title":"Int J Environ Res Public Health"},{"key":"421_CR71","doi-asserted-by":"publisher","first-page":"5168","DOI":"10.1016\/j.bmcl.2016.09.076","volume":"26","author":"F Schmitt","year":"2016","unstructured":"Schmitt F, Draut H, Biersack B, Schobert R (2016) Halogenated naphthochalcones and structurally related naphthopyrazolines with antitumor activity. Bioorg Med Chem Lett 26:5168\u20135171","journal-title":"Bioorg Med Chem Lett"},{"key":"421_CR72","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1021\/acs.jmedchem.5b01644","volume":"59","author":"SM Schmitt","year":"2016","unstructured":"Schmitt SM, Stefan K, Wiese M (2016) Pyrrolopyrimidine derivatives as novel inhibitors of multidrug resistance-associated protein 1 (MRP1, ABCC1). J Med Chem 59:3018\u20133033","journal-title":"J Med Chem"},{"key":"421_CR73","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1021\/acs.molpharmaceut.6b00754","volume":"14","author":"N Sjostedt","year":"2017","unstructured":"Sjostedt N, Holvikari K, Tammela P, Kidron H (2017) Inhibition of breast cancer resistance protein and multidrug resistance associated protein 2 by natural compounds and their derivatives. Mol Pharm 14:135\u2013146","journal-title":"Mol Pharm"},{"key":"421_CR74","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00280-016-3127-2","volume":"78","author":"JG Song","year":"2016","unstructured":"Song JG, Lee YS, Park J-A, Lee E-H, Lim S-J, Yang SJ, Zhao M, Lee K, Han H-K (2016) Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein. Cancer Chemother Pharmacol 78:735\u2013744","journal-title":"Cancer Chemother Pharmacol"},{"key":"421_CR75","doi-asserted-by":"publisher","first-page":"6121","DOI":"10.1021\/acs.jmedchem.6b00035","volume":"59","author":"A Spindler","year":"2016","unstructured":"Spindler A, Stefan K, Wiese M (2016) Synthesis and investigation of tetrahydro-beta-carboline derivatives as inhibitors of the breast cancer resistance protein (ABCG2). J Med Chem 59:6121\u20136135","journal-title":"J Med Chem"},{"key":"421_CR76","doi-asserted-by":"publisher","first-page":"22644","DOI":"10.1074\/jbc.M212399200","volume":"278","author":"M Suzuki","year":"2003","unstructured":"Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y (2003) ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 278:22644\u201322649","journal-title":"J Biol Chem"},{"key":"421_CR77","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ejphar.2013.11.005","volume":"723","author":"KW Tan","year":"2014","unstructured":"Tan KW, Killeen DP, Li Y, Paxton JW, Birch NP, Scheepens A (2014) Dietary polyacetylenes of the falcarinol type are inhibitors of breast cancer resistance protein (BCRP\/ABCG2). Eur J Pharmacol 723:346\u2013352","journal-title":"Eur J Pharmacol"},{"key":"421_CR78","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/j.foodchem.2012.12.021","volume":"138","author":"KW Tan","year":"2013","unstructured":"Tan KW, Li Y, Paxton JW, Birch NP, Scheepens A (2013) Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP\/ABCG2). Food Chem 138:2267\u20132274","journal-title":"Food Chem"},{"key":"421_CR79","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1021\/jm2016528","volume":"55","author":"G Valdameri","year":"2012","unstructured":"Valdameri G, Gauthier C, Terreux R, Kachadourian R, Day BJ, Winnischofer SMB, Rocha MEM, Frachet V, Ronot X, Di Pietro A, Boumendjel A (2012) Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity. J Med Chem 55:3193\u20133200","journal-title":"J Med Chem"},{"key":"421_CR80","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1021\/jm201404w","volume":"55","author":"G Valdameri","year":"2012","unstructured":"Valdameri G, Genoux-Bastide E, Peres B, Gauthier C, Guitton J, Terreux R, Winnischofer SMB, Rocha MEM, Boumendjel A, Di Pietro A (2012) Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein. J Med Chem 55:966\u2013970","journal-title":"J Med Chem"},{"key":"421_CR81","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1021\/acsmedchemlett.6b00046","volume":"7","author":"A Wieczorek","year":"2016","unstructured":"Wieczorek A, Blauz A, Zakrzewski J, Rychlik B, Plazuk D (2016) Ferrocenyl 2,5-piperazinediones as tubulin-binding organometallic ABCB(1) and ABCG(2) inhibitors active against MDR cells. ACS Med Chem Lett 7:612\u2013617","journal-title":"ACS Med Chem Lett"},{"key":"421_CR82","first-page":"609","volume":"8","author":"E Winter","year":"2014","unstructured":"Winter E, Gozzi GJ, Chiaradia-Delatorre LD, Daflon-Yunes N, Terreux R, Gauthier C, Mascarello A, Leal PC, Cadena SM, Yunes RA, Nunes RJ, Creczynski-Pasa TB, Di Pietro A (2014) Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position. Drug Des Dev Ther 8:609\u2013619","journal-title":"Drug Des Dev Ther"},{"key":"421_CR83","doi-asserted-by":"publisher","first-page":"9849","DOI":"10.1021\/jm401649j","volume":"56","author":"E Winter","year":"2013","unstructured":"Winter E, Lecerf-Schmidt F, Gozzi G, Peres B, Lightbody M, Gauthier C, Ozvegy-Laczka C, Szakacs G, Sarkadi B, Creczynski-Pasa TB, Boumendjel A, Di Pietro A (2013) Structure\u2013activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2. J Med Chem 56:9849\u20139860","journal-title":"J Med Chem"},{"key":"421_CR84","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1021\/jm401879z","volume":"57","author":"E Winter","year":"2014","unstructured":"Winter E, Neuenfeldt PD, Chiaradia-Delatorre LD, Gauthier C, Yunes RA, Nunes RJ, Creczynski-Pasa TB, Di Pietro A (2014) Symmetric Bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones. J Med Chem 57:2930\u20132941","journal-title":"J Med Chem"},{"key":"421_CR85","unstructured":"(2015) MOE molecular simulation package. Chemical Computing Group ULC, Montreal"},{"key":"421_CR86","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1021\/mp100465q","volume":"8","author":"L Chen","year":"2011","unstructured":"Chen L, Li Y, Zhao Q, Peng H, Hou T (2011) ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and Naive bayesian classification techniques. Mol Pharm 8:889\u2013900","journal-title":"Mol Pharm"},{"key":"421_CR87","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1021\/mp300023x","volume":"9","author":"S Wang","year":"2012","unstructured":"Wang S, Li Y, Wang J, Chen L, Zhang L, Yu H, Hou T (2012) ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage. Mol Pharm 9:996\u20131010","journal-title":"Mol Pharm"},{"key":"421_CR88","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1021\/mp400450m","volume":"11","author":"D Li","year":"2014","unstructured":"Li D, Chen L, Li Y, Tian S, Sun H, Hou T (2014) ADMET evaluation in drug discovery. 13. Development of in silico prediction models for P-glycoprotein substrates. Mol Pharm 11:716\u2013726","journal-title":"Mol Pharm"},{"key":"421_CR89","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/jcc.21707","volume":"32","author":"CW Yap","year":"2011","unstructured":"Yap CW (2011) PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints. J Comput Chem 32:1466\u20131474","journal-title":"J Comput Chem"},{"key":"421_CR90","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2307\/2348448","volume":"44","author":"SP Brooks","year":"1995","unstructured":"Brooks SP, Morgan BJT (1995) Optimization using simulated annealing. Statistician 44:241\u2013257","journal-title":"Statistician"},{"key":"421_CR91","unstructured":"Kuhn M. Feature selection using simulated annealing. https:\/\/topepo.github.io\/caret\/feature-selection-using-simulated-annealing.html. Accessed 16 Apr"},{"key":"421_CR92","unstructured":"Kuhn M. Package \u2018caret\u2019. https:\/\/cran.r-project.org\/web\/packages\/caret\/caret.pdf. Accessed 16 Apr"},{"key":"421_CR93","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1021\/jm0303195","volume":"47","author":"XY Xia","year":"2004","unstructured":"Xia XY, Maliski EG, Gallant P, Rogers D (2004) Classification of kinase inhibitors using a Bayesian model. J Med Chem 47:4463\u20134470","journal-title":"J Med Chem"},{"key":"421_CR94","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/wcms.1183","volume":"4","author":"JB Mitchell","year":"2014","unstructured":"Mitchell JB (2014) Machine learning methods in chemoinformatics. Wiley Interdiscip Rev Comput Mol Sci 4:468\u2013481","journal-title":"Wiley Interdiscip Rev Comput Mol Sci"},{"key":"421_CR95","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/1062936X.2016.1229691","volume":"27","author":"Y Ren","year":"2016","unstructured":"Ren Y, Zhou L, Yang L, Liu P, Zhao B, Liu H (2016) Predicting the aquatic toxicity mode of action using logistic regression and linear discriminant analysis. SAR QSAR Environ Res 27:721\u2013746","journal-title":"SAR QSAR Environ Res"},{"key":"421_CR96","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0167-9473(01)00065-2","volume":"38","author":"JH Friedman","year":"2002","unstructured":"Friedman JH (2002) Stochastic gradient boosting. Comput Stat Data Anal 38:367\u2013378","journal-title":"Comput Stat Data Anal"},{"key":"421_CR97","unstructured":"Dahl GE, Jaitly N, Salakhutdinov R. Multi-task neural networks for QSAR predictions. arXiv e-prints. 2014. https:\/\/ui.adsabs.harvard.edu\/abs\/2014arXiv1406.1231D. Accessed 01 June 2014"},{"key":"421_CR98","first-page":"2951","volume":"2012","author":"J Snoek","year":"2012","unstructured":"Snoek J, Larochelle H, Adams RP (2012) Practical bayesian optimization of machine learning algorithms. Adv Neural Inf Process Syst 2012:2951\u20132959","journal-title":"Adv Neural Inf Process Syst"},{"key":"421_CR99","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13321-017-0226-y","volume":"9","author":"A Koutsoukas","year":"2017","unstructured":"Koutsoukas A, Monaghan KJ, Li X, Huan J (2017) Deep-learning: investigating deep neural networks hyper-parameters and comparison of performance to shallow methods for modeling bioactivity data. J Cheminform 9:42","journal-title":"J Cheminform"},{"key":"421_CR100","unstructured":"Guidance document on the validation of (quantitative) structure\u2013activity relationship [(Q) SAR] models. OECD Series on Testing and Assessment, 1\u2013154, 2014"},{"key":"421_CR101","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fenvs.2015.00080","volume":"3","author":"A Mayr","year":"2016","unstructured":"Mayr A, Klambauer G, Unterthiner T, Hochreiter S (2016) DeepTox: toxicity prediction using deep learning. Front Environ Sci 3:80","journal-title":"Front Environ Sci"},{"key":"421_CR102","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.1039\/C8SC00148K","volume":"9","author":"A Mayr","year":"2018","unstructured":"Mayr A, Klambauer G, Unterthiner T, Steijaert M, Wegner JK, Ceulemans H, Clevert D-A, Hochreiter S (2018) Large-scale comparison of machine learning methods for drug target prediction on ChEMBL. Chem Sci 9:5441\u20135451","journal-title":"Chem Sci"},{"key":"421_CR103","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/026119290503300508","volume":"33","author":"J Jaworska","year":"2005","unstructured":"Jaworska J, Nikolova-Jeliazkova N, Aldenberg T (2005) QSAR applicability domain estimation by projection of the training set in descriptor space: a review. Atla-Altern Lab Anim 33:445\u2013459","journal-title":"Atla-Altern Lab Anim"},{"key":"421_CR104","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.3390\/molecules17054791","volume":"17","author":"F Sahigara","year":"2012","unstructured":"Sahigara F, Mansouri K, Ballabio D, Mauri A, Consonni V, Todeschini RJM (2012) Comparison of different approaches to define the applicability domain of QSAR models. Molecules 17:4791\u20134810","journal-title":"Molecules"},{"key":"421_CR105","unstructured":"Nina Nikolova-Jeliazkova JJ (2006) AmbitDiscovery-v0.04"},{"key":"421_CR106","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1021\/acs.molpharmaceut.7b00631","volume":"14","author":"T Lei","year":"2017","unstructured":"Lei T, Sun H, Kang Y, Zhu F, Liu H, Zhou W, Wang Z, Li D, Li Y, Hou T (2017) ADMET evaluation in drug discovery. 18. Reliable prediction of chemical-induced urinary tract toxicity by boosting machine learning-approaches. Mol Pharm 14:3935\u20133953","journal-title":"Mol Pharm"},{"key":"421_CR107","unstructured":"Fisher A, Rudin C, Dominici F (2018) All models are wrong but many are useful: variable importance for black-box, proprietary, or misspecified prediction models, using model class reliance. arXiv preprint arXiv:1801.01489"},{"key":"421_CR108","unstructured":"Burzykowski PBT. Chapter 15 feature importance. https:\/\/pbiecek.github.io\/PM_VEE\/featureImportance.html. Accessed 24 Sept"},{"key":"421_CR109","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2015.01.009","volume":"86","author":"S Tian","year":"2015","unstructured":"Tian S, Wang J, Li Y, Li D, Xu L, Hou T (2015) The application of in silico drug-likeness predictions in pharmaceutical research. Adv Drug Deliv Rev 86:2\u201310","journal-title":"Adv Drug Deliv Rev"},{"key":"421_CR110","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1021\/jm060333s","volume":"50","author":"BF Jensen","year":"2007","unstructured":"Jensen BF, Vind C, Padkj\u00e6r SB, Brockhoff PB, Refsgaard HH (2007) In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using Gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors. J Med Chem 50:501\u2013511","journal-title":"J Med Chem"},{"key":"421_CR111","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/minf.201500055","volume":"35","author":"C Zhang","year":"2016","unstructured":"Zhang C, Cheng F, Li W, Liu G, Lee PW, Tang Y (2016) In silico prediction of drug induced liver toxicity using substructure pattern recognition method. Mol Inform 35:136\u2013144","journal-title":"Mol Inform"},{"key":"421_CR112","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.addr.2008.09.007","volume":"61","author":"C Hegedus","year":"2009","unstructured":"Hegedus C, Szakacs G, Homolya L, Orban TI, Telbisz A, Jani M, Sarkadi B (2009) Ins and outs of the ABCG2 multidrug transporter: an update on in vitro functional assays. Adv Drug Deliv Rev 61:47\u201356","journal-title":"Adv Drug Deliv Rev"},{"key":"421_CR113","doi-asserted-by":"publisher","first-page":"e90689","DOI":"10.1371\/journal.pone.0090689","volume":"9","author":"Y-L Ding","year":"2014","unstructured":"Ding Y-L, Shih Y-H, Tsai F-Y, Leong MK (2014) In silico prediction of inhibition of promiscuous breast cancer resistance protein (BCRP\/ABCG2). PLoS ONE 9:e90689","journal-title":"PLoS ONE"},{"key":"421_CR114","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1158\/1535-7163.MCT-12-0215","volume":"11","author":"Y Wei","year":"2012","unstructured":"Wei Y, Ma Y, Zhao Q, Ren Z, Li Y, Hou T, Peng H (2012) New use for an old drug: inhibiting ABCG2 with sorafenib. Mol Cancer Ther 11:1693\u20131702","journal-title":"Mol Cancer Ther"},{"key":"421_CR115","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1007\/s11095-009-9896-0","volume":"26","author":"P Matsson","year":"2009","unstructured":"Matsson P, Pedersen JM, Norinder U, Bergstrom CAS, Artursson P (2009) Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 26:1816\u20131831","journal-title":"Pharm Res"},{"key":"421_CR116","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ijc.20216","volume":"110","author":"M Yoshikawa","year":"2004","unstructured":"Yoshikawa M, Ikegami Y, Hayasaka S, Ishii K, Ito A, Sano K, Suzuki T, Togawa T, Yoshida H, Soda H (2004) Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer 110:921\u2013927","journal-title":"Int J Cancer"},{"key":"421_CR117","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1021\/ci990307l","volume":"39","author":"SA Wildman","year":"1999","unstructured":"Wildman SA, Crippen GM (1999) Prediction of physicochemical parameters by atomic contributions. J Chem Inf Comput Sci 39:868\u2013873","journal-title":"J Chem Inf Comput Sci"},{"key":"421_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13321-017-0232-0","volume":"9","author":"EB Lenselink","year":"2017","unstructured":"Lenselink EB, ten Dijke N, Bongers B, Papadatos G, van Vlijmen HWT, Kowalczyk W, Ijzerman AP, van Westen GJP (2017) Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set. J Cheminform 9:1\u201314","journal-title":"J Cheminform"},{"key":"421_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13321-016-0121-y","volume":"8","author":"F Montanari","year":"2016","unstructured":"Montanari F, Zdrazil B, Digles D, Ecker GF (2016) Selectivity profiling of BCRP versus P-gp inhibition: from automated collection of polypharmacology data to multi-label learning. J Cheminform 8:1\u201313","journal-title":"J Cheminform"},{"key":"421_CR120","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.1021\/acs.jcim.9b00801","volume":"59","author":"Z Wu","year":"2019","unstructured":"Wu Z, Lei T, Shen C, Wang Z, Cao D, Hou T (2019) ADMET evaluation in drug discovery. 19. Reliable prediction of human cytochrome P450 inhibition using artificial intelligence approaches. J Chem Inf Model 59:4587\u20134601","journal-title":"J Chem Inf Model"},{"key":"421_CR121","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s11095-012-0935-x","volume":"30","author":"A Sedykh","year":"2013","unstructured":"Sedykh A, Fourches D, Duan J, Hucke O, Garneau M, Zhu H, Bonneau P, Tropsha A (2013) Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res 30:996\u20131007","journal-title":"Pharm Res"},{"key":"421_CR122","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/1062936X.2014.976265","volume":"25","author":"S Eric","year":"2014","unstructured":"Eric S, Kalinic M, Ilic K, Zloh M (2014) Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein. SAR QSAR Environ Res 25:955\u2013982","journal-title":"SAR QSAR Environ Res"},{"key":"421_CR123","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s12668-016-0246-5","volume":"6","author":"TR Gimadiev","year":"2016","unstructured":"Gimadiev TR, Madzhidov TI, Marcou G, Varnek A (2016) Generative topographic mapping approach to modeling and chemical space visualization of human intestinal transporters. BioNanoScience 6:464\u2013472","journal-title":"BioNanoScience"}],"container-title":["Journal of Cheminformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13321-020-00421-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13321-020-00421-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13321-020-00421-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T17:53:26Z","timestamp":1666029206000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcheminf.biomedcentral.com\/articles\/10.1186\/s13321-020-00421-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":123,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["421"],"URL":"https:\/\/doi.org\/10.1186\/s13321-020-00421-y","relation":{},"ISSN":["1758-2946"],"issn-type":[{"value":"1758-2946","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]},"assertion":[{"value":"27 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}